Focused On-demand Library for Wings apart-like protein homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q7Z5K2

UPID:

WAPL_HUMAN

Alternative names:

Friend of EBNA2 protein; WAPL cohesin release factor

Alternative UPACC:

Q7Z5K2; A7E2B5; Q5VSK5; Q8IX10; Q92549

Background:

The Wings apart-like protein homolog, also known as Friend of EBNA2 protein and WAPL cohesin release factor, plays a pivotal role in cell division. It is a key regulator of sister chromatid cohesion in mitosis, ensuring accurate chromosome partitioning by negatively regulating cohesin association with chromatin. This protein is crucial during both interphase for sister chromatid cohesion and the early stages of mitosis for sister-chromatid resolution. Its function of coupling DNA replication to sister chromatid cohesion underscores its importance in both meiotic and mitotic cells, as well as in DNA repair processes.

Therapeutic significance:

Understanding the role of Wings apart-like protein homolog could open doors to potential therapeutic strategies.